Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis
Luise Maute(Goethe University Frankfurt), Lothar Bergmann(Universität Ulm), Christoph Kahl(Klinikum Magdeburg), Ulrich Kube(Goethe Institut), Steffen Weikert(St. Hedwig-Krankenhaus), Viktor Grünwald(Deutsche Schmerzgesellschaft), Iris Burkholder(German Cancer Research Center), Thomas Gauler
Cited by 16
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617